FDA Approves Cuvrior (trientine tetrahydrochloride) for the Treatment of Wilson ’s disease

Paris, France 2 May 2022– Orphalan SA (“Orphalan” or“the Company”), an international orphan drug development and commercialisation company, today announces approval of Cuvrior™, a new salt of trientine...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news